Egypt Hepatitis C Drug Market Insights and In-Depth Analysis 2023-2028 with Types, Products and Key Players

The Egypt Hepatitis C Drug Market 2023 Report makes available the current and forthcoming technical and financial details of the industry. It is one of the most comprehensive and important additions to the Prudent Markets archive of market research studies. It offers detailed research and analysis of key aspects of the global Egypt Hepatitis C Drug market. This report explores all the key factors affecting the growth of the global Egypt Hepatitis C Drug market, including demand-supply scenario, pricing structure, profit margins, production, and value chain analysis.

Get PDF Sample Report Now! @ https://www.prudentmarkets.com/sample-request/141594/

Egypts Hepatitis C drug market size stood at USD xx billion in 2019 and is projected to reach USD xx billion by 2028, exhibiting a CAGR of xx% during the forecast period.

Hepatitis C is a viral infection that causes severe damage such as inflammation of the liver and can spread through contaminated blood. The advanced stages of hepatitis C can also lead to liver damage, thereby creating severe health risks. The severity of hepatitis C has created a huge emphasis on the research and development of drugs associated with the treatment of this disease.

Egypt continues to report one of the highest incidences of Hepatitis C (HCV) in the world, estimated at 10-15mn sufferers in 2017. Secondary problems associated with HCV include cirrhosis of the liver, which was responsible for around half a million DALYs lost in Egypt in 2017. The Egyptian government is upholding its pledge towards reducing the HCV burden in the country. The MoH recently announced its plans to strengthen the national campaign against the virus, largely through greater cooperation with pharmaceutical manufacturers of antivirals.

Market Drivers

The escalating demand for hepatitis C drugs has yielded several regulatory approvals for associated drugs. Increasing regulatory approvals for related drugs and recombinant products will constitute an increase in the Hepatitis C Drugs Market value in the coming years.

Egypt, one of the countries with the largest burden of hepatitis C infection in the world, has made significant advances since 2018 towards hepatitis C elimination through a large countrywide public health effort to screen the entire population aged 18 years and older (a target population of 62.5 million) and link those in need to care. Nearly 50 million adults and 9 million children aged 1218 years were screened, and 1.5 million additional persons had started treatment by mid-2019. This constitutes one of the largest public health efforts to date towards hepatitis C elimination in low- and middle-income countries. Egypt now plans to support other countries in the sub-Saharan African region in their scale-up efforts.

According to World Banks projections, if Egypt continues its current treatment path, it will spend nearly $4 billion on Hepatitis C by 2030. This will improve and boost the Hepatitis C drug demand in the Egyptian market.

However, Egypt and Pakistan reduced their order volumes by 60 percent in 2019. These countries have treated the majority of their diagnosed patients and are now focusing on case-finding activities. As countries approach elimination by treating most of their patients, the demand for DAAs in those specific countries might peak and then decline.

To Know More About COVID-19 Impact On Egypt Hepatitis C Drug Market @ https://www.prudentmarkets.com/sample-request/141594/

By Drug Type

On the basis of antiviral drug type, the market is segmented into entecavir, tenofovir, lamivudine, adefovir, telbivudine, and others

By Route of Administration

By route of administration, the treatment market has been segmented into oral and parenteral and others.

By End-User

By end-user, the treatment market is segmented into hospital and Clinics, Diagnostic Centres, and others.

Distribution Channel

On the basis of distribution channel, the global hepatic antiviral drugs market can be segmented into hospital pharmacy, online pharmacy, and retail pharmacy.

Major Players

Egypt's Hepatitis C treatment market is fragmented into local and global companies including Hikma, Novartis, Roche, AstraZeneca, Sanofi, EIPICO, GSK, Pharco, Amoun Pharmaceutical Company, Eva Pharma, Pfizer, Magic Pharma, Pharmed, Hetero. These are expected to lead the market in the forecast period.

In 2015, the Egyptian government successfully negotiated with US-based Gilead Sciences' in importing its Hepatitis C treatments of Sovaldi (sofosbuvir) and Harvoni (ledipasvir/sofosbuvir) at heavily discounted prices.

Egypt, India, and Pakistan have secured very low prices for DAAs across regimens as they are scaling up public programs rapidly and moving towards HCV elimination.

Prudent Markets provides attractive discounts that fit your needs. Customization of the reports as per your requirement is also offered. Get in touch with our sales team, who will guarantee you a report that suits your needs.

Speak To Our Analyst For A Discussion On The Above Findings, And Ask For A Discount On The Report @ https://www.prudentmarkets.com/discount-request/141594/

The report covers the competitive analysis of the market. As the demand is driven by a buyer's paying capacity and the rate of item development, the report shows the important regions that will direct growth. This section exclusively shares insight into the budget reports of big-league members of the market helping key players and new entrants understand the potential of investments in the Global Egypt Hepatitis C Drug Market. It can be better employed by both traditional and new players in the industry for complete know-how of the market.

Strategic Points Covered in Table of Content of Global Egypt Hepatitis C Drug Market:

Chapter 1: Introduction, market driving force product Objective of Study and Research Scope the Egypt Hepatitis C Drug market
Chapter 2: Exclusive Summary - the basic information of the Egypt Hepatitis C Drug Market.
Chapter 3: Displaying the Market Dynamics- Drivers, Trends and Challenges & Opportunities of the Egypt Hepatitis C Drug
Chapter 4: Presenting the Egypt Hepatitis C Drug Market Factor Analysis, Porters Five Forces, Supply/Value Chain, PESTEL analysis, Market Entropy, Patent/Trademark Analysis.
Chapter 5: Displaying the by Type, End User and Region/Country
Chapter 6: Evaluating the leading manufacturers of the Egypt Hepatitis C Drug market which consists of its Competitive Landscape, Peer Group Analysis, BCG Matrix & Company Profile
Chapter 7: To evaluate the market by segments, by countries and by Manufacturers/Company with revenue share and sales by key countries in these various regions
Chapter 8 & 9: Displaying the Appendix, Methodology and Data Source

Any Questions? Feel Free To Enquire Here. We Will put you on the Right Path @ https://www.prudentmarkets.com/enquiry-request/141594/

Free Customization on the basis of client requirements on Immediate purchase:
1- Free country-level breakdown of any 5 countries of your interest.
2- Competitive breakdown of segment revenue by market players.

Customization of the Report:
This report can be customized to meet the client's requirements. Please connect with our sales team (sales@prudentmarkets.com), who will ensure that you get a report that suits your needs. You can also get in touch with our executives on +91 83560 50278 || USA/Canada(Toll Free): 1800-601-6071 to share your research requirements.

Get ready to Recognize the pros and cons of the regulatory framework, local reforms, and its effect on the Industry. Understand how the Leaders in Intelligent Network are keeping themselves one stage forward with our most up-to-date survey analysis.

In conclusion, the Egypt Hepatitis C Drug Market report is a genuine source for accessing the research data which is projected to exponentially grow your business. The report provides information such as economic scenarios, benefits, limits, trends, market growth rates, and figures. SWOT analysis and PESTLE analysis is also incorporated in the report.

Contact Us:
Allan Carter
Andheri, Maharashtra, 400102
USA/Canada(Toll Free): 1800-601-6071
Direct Line: +91 83560 50278
Mail: sales@prudentmarkets.com
Web: www.prudentmarkets.com

About Us:
We are leaders in market analytics, business research, and consulting services for Fortune 500 companies, start-ups, financial & government institutions. Since we understand the criticality of data and insights, we have associated with the top publishers and research firms all specialized in specific domains, ensuring you will receive the most reliable and up to date research data available. To be at our client's disposal whenever they need help on market research and consulting services. We also aim to be their business partners when it comes to making critical business decisions around new market entry, M&A, competitive Intelligence and strategy.

This release was published on openPR.